| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 11.40▼ | 11.41▼ | 11.39▲ | 11.66▼ | 6.58▲ |
| MA10 | 11.55▼ | 11.33▲ | 11.43▼ | 10.50▲ | 3.40▲ |
| MA20 | 11.55▼ | 12.19▼ | 11.78▼ | 6.00▲ | 2.04▲ |
| MA50 | 12.67▼ | 11.88▼ | 10.85▲ | 2.54▲ | 1.74▲ |
| MA100 | 11.87▼ | 10.27▲ | 6.88▲ | 1.67▲ | 6.81▲ |
| MA200 | 12.16▼ | 5.80▲ | 3.54▲ | 1.52▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.015▲ | -0.133▼ | -0.197▼ | 0.566▲ | 1.390▲ |
| RSI | 41.192▼ | 46.413▼ | 49.922▼ | 69.786▲ | 80.084▲ |
| STOCH | 45.224 | 35.098 | 19.197▼ | 63.755 | 44.924 |
| WILL %R | -49.383 | -84.793▼ | -88.384▼ | -28.476 | -28.452 |
| CCI | -38.529 | -41.094 | -49.014 | 58.134 | 193.104▲ |
|
Wednesday, May 20, 2026 05:59 AM
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapiesSegment ...
|
|
Saturday, May 16, 2026 05:11 PM
Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.
|
|
Tuesday, May 12, 2026 09:24 AM
Loss per share narrowed to $6.95 from a loss of $57.76 per share last year. ・Last week, the firm said its therapy completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 20/05/26 | 10.99 | 11.80 | 10.99 | 11.40 | 73,591 |
| 19/05/26 | 11.51 | 12.03 | 10.50 | 11.45 | 77,775 |
| 18/05/26 | 13.32 | 14.19 | 11.25 | 12.25 | 239,159 |
| 15/05/26 | 9.21 | 15.00 | 9.20 | 13.63 | 1,374,290 |
| 14/05/26 | 11.70 | 11.965 | 9.56 | 9.56 | 465,739 |
| 13/05/26 | 14.37 | 14.59 | 11.70 | 12.14 | 1,781,916 |
| 12/05/26 | 7.46 | 15.88 | 7.22 | 12.01 | 19,408,131 |
| 11/05/26 | 7.40 | 7.90 | 6.56 | 7.21 | 488,950 |
| 08/05/26 | 7.74 | 8.11 | 6.3878 | 7.53 | 1,460,833 |
| 07/05/26 | 6.96 | 8.49 | 6.2507 | 7.82 | 10,258,009 |
|
|
||||
|
|
||||
|
|